错配修复基因hMLH1、hMSH2、hMSH6和hPMS2在左、右半结肠癌表达差异研究

详细信息    查看全文 | 推荐本文 |

英文篇名：Differential Expression of Mismatch Repair Genes hMLH1,hMSH2,hMSH6 and h PMS2 in Left and Right Colon Cancer 作者：王磊 ; 张宁妹 ; 张晓莉 ; 罗廷燕 ; 杨泽明 ; 李海 英文作者：WANG Lei;ZHANG Ningmei;ZHANG Xiaoli;LUO Tingyan;YANG Zeming;LI Hai;Ningxia Medical University;Tumor Hospital,the General Hospital of Ningxia Medical University;Yinchuan Maternal and Child Health Hospital;Guo Long Hospital;General Hospital of Ningxia Medical University; 关键词：左半结肠癌 ; 右半结肠癌 ; 错配修复基因 ; 免疫组化学 英文关键词：left sided colon cancer;;right sided colon cancer;;mismatch repair gene;;immunohistochemistry 中文刊名：XNXY 英文刊名：Journal of Ningxia Medical University 机构：宁夏医科大学;宁夏医科大学总医院肿瘤医院;银川市妇幼保健院;银川国龙医院;宁夏医科大学总医院; 出版日期：2019-03-30 出版单位：宁夏医科大学学报 年：2019 期：v.41;No.246 基金：宁夏医科大学优势学科群建设科研项目(2001060603) 语种：中文; 页：XNXY201903004 页数：5 CN：03 ISSN：64-1064/R 分类号：26-29+38

摘要

目的探讨错配修复基因(MMR)hMLH1、hMSH2、hMSH6和hPMS2表达在左半结肠癌和右半结肠癌中的差异。方法采用免疫组化PV-9000二步法检测左半结肠癌185例和右半结肠癌197例中的癌组织hMLH1、hMSH2、hMSH6和hPMS2表达缺失情况并进行数据分析。结果左半结肠癌中hMLH1、hMSH2、hMSH6、hPMS2表达缺失率分别为10.3%、1.6%、2.7%、20.0%,右半结肠癌中hMLH1、hMSH2、hMSH6、hPMS2表达缺失率分别为21.3%、7.6%、5.6%、29.4%。左半结肠癌患者hMLH1、hMSH2、hPMS2表达缺失率均低于右半结肠癌患者(P<0.05),hMSH6表达缺失率差异无统计学意义(P>0.05)。结论在左右半结肠癌组织中存在错配修复基因hMLH1、hMSH2、hMSH6、hPMS2的表达缺失,且与肿瘤位置密切相关。通过免疫组化法检测MMR中hMLH1、hMSH2、hMSH6、hPMS2的突变,为拟定个体化治疗方案提供有参考价值的依据。
        Objective To investigate the difference of expression of mismatch repair genes(MMR)hMLH1,hMSH2,hMSH6 and hPMS2 in left and right colon cancer. Methods The expression of hMLH1,hMSH2,hMSH6 and hPMS2 in 185 cases of left colon cancer and 197 cases of right colon cancer were detected by immunohistochemical PV-9000 two-step method and the data were analyzed. Results The expression deletion rates of hMLH1,hMSH2,hMSH6 and hPMS2 in left colon cancer were 10.3%,1.6%,2.7% and 20.0%,respectively. The deletion rates of hMLH1,hMSH2,hMSH6 and hPMS2 in right colon cancer were 21.3%,7.6%,5.6% and 29.4%,respectively. The results of data analysis showed that there were significant differences in the expression of hMLH1,hMSH2 and hPMS2 between the two groups(P<0.05),and no significant difference in the expression of hMSH6 between the two groups(P>0.05). Conclusion There are deletions of mismatch repair genes hMLH1,hMSH2,hMSH6 and hPMS2 in the left and right colon cancer tissues,which are closely related to the location of the tumors(the deletion rate of right colon cancer is significantly higher than that of left colon cancer). The mutations of hMLH1,hMSH2,hMSH6 and hPMS2 in MMR are detected by immunohistochemical method,which may provide a reference for the formulation of individualized treatment.

引文

[1]Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
    [2]陈万青,张思维,郑荣寿,等.中国2009年恶性肿瘤发病和死亡分析[J].中国肿瘤,2013,22(1):2-12.
    [3]Bufill JA.Colorectal cancer:evidence for distinct genetic categories based on proximal or distal tumor location[J].Ann Intern Med,1990,113(10):779.
    [4]马赛.基因错配修复系统作用机制及其与常见恶性肿瘤的关系[J].武警医学,2017,28(2):207-211.
    [5]胡俊杰,周志祥,梁建伟,等.左、右半结肠癌患者临床病理特点及预后差异分析[J].中华医学杂志,2015,95(28):2268-2271.
    [6]Hansen IO,Jess P.Possible better long-term survival in left versus right-sided colon cancer-a systematic review[J].Dan Med J,2012,59(6):4444.
    [7]Hussain M,Waqas O,Hassan U,et al.Right-sided and left-sided colon cancers are two distinct disease entities:An analysis of 200 cases in pakistan[J].Asian Pac J Cancer Prev,2016,17(5):2545-2548.
    [8]Gao P,Song YX,Xu YY,et al.Does the prognosis of colorectal mucinous carcinoma depend upon the primary tumour site Results from two independent databases[J].Histopathology,2013,63(5):603-615.
    [9]Yoon YS,Yu CS,Kim TW,et al.Mismatch repair status in sporadic colorectal cancer:immunohistochemistry and microsatellite instability analyses[J].J Gastroenterol Hepatol,2011,26(12):1733-1739.
    [10]Kim HR,Kim HC,Yun HR,et al.An alternative pathway in colorectal carcinogenesis based on the mismatch repair system and p53 expression in Korean patients with sporadic colorectal cancer[J].Ann Surg Oncol,2013,20(12):4031-4040.
    [11]于显博,王海江,孙振强,等.散发性结直肠癌患者错配修复基因蛋白表达水平及其临床意义[J].中国全科医学,2014,17(8):883-887.
    [12]邱春华,张志宏,董丹丹,等.错配修复基因蛋白在结直肠癌诊治中的临床应用[J].中国肿瘤临床,2018,45(19):1005-1008.
    [13]徐恩伟.结直肠癌DNA错配修复蛋白和微卫星不稳定性与P53蛋白表达关系的研究[J].中国药物与临床,2016,16(12):1733-1734.
    [14]Burt RW,Barthel JS,Dunn KB,et al.NCCN clinical practice guidelines in oncology.Colorectal cancer screening[J].J Natl Compr Canc Netw,2010,8(1):8-61.